Table 2. Clinicopathologic features by HER2 status.

Characteristics	Categories	HER2+	HER2−	P value
Median age at diagnosis, years (range)	-	43.6 (17.6–74.9)	49.4 (15.8–82.1)	0.094
Ethnic group	Chinese (n = 80)	18 (23%)	62 (78%)	0.052
	Malays (n = 16)	9 (56%)	7 (44%)
	Indians (n = 6)	1 (17%)	5 (83%)
	Others (n = 11)	3 (27%)	8 (73%)
Smoking history	Non-smoker (n = 29)	9 (31%)	20 (69%)	0.720
	Ever-smoker (n = 14)	3 (21%)	11 (79%)
Family history of cancer	Negative (n = 39)	12 (31%)	27 (69%)	0.728
	Positive (n = 11)	4 (36%)	7 (64%)
Presence of comorbidities	No (n = 40)	14 (35%)	26 (65%)	0.267
	Yes (n = 68)	17 (25%)	51 (75%)
Stage at diagnosis	I (n = 88)	29 (33%)	59 (67%)	0.285
	II (n = 5)	0 (-)	5 (100%)
	III (n = 11)	2 (18%)	9 (82%)
	IV (n = 3)	0 (-)	3 (100%)
Tumour differentiation/grade	well (n = 64)	19 (30%)	45 (70%)	0.717
	moderate (n = 28)	10 (36%)	18 (64%)
	poor (n = 9)	2 (22%)	7 (78%)
Tumour type	Mixed borderline (n = 45)	17 (38%)	28 (62%)	0.063
	Non-borderline (n = 65)	14 (22%)	51 (78%)
Ovarian surface involvement	No (n = 66)	23 (35%)	43 (65%)	0.075
	Yes (n = 38)	7 (18%)	31 (82%)
Lymphovascular invasion	No (n = 100)	29 (29%)	71 (71%)	0.186
	Yes (n = 7)	0 (-)	7 (100%)
Median CA125, U/mL (range)	-	37.2 (6.1–415.7)	102.5 (3.0–8812.5)	0.024
Received OGD	No (n = 93)	29 (31%)	64 (69%)	0.148
	Yes (n = 16)	2 (13%)	14 (88%)
Received colonoscopy	No (n = 90)	29 (32%)	61 (68%)	0.057
	Yes (n = 19)	2 (11%)	17 (89%)
Received appendectomy	No (n = 51)	15 (29%)	36 (71%)	0.833
	Yes (n = 58)	16 (28%)	42 (72%)
Received omentectomy	No (n = 7)	3 (43%)	4 (57%)	0.400
	Yes (n = 103)	28 (27%)	75 (73%)
Received chemotherapy	No (n = 57)	18 (32%)	39 (68%)	0.419
	Yes (n = 49)	12 (24%)	37 (76%)
Received adjuvant chemotherapy	No (n = 69)	19 (28%)	50 (72%)	0.745
	Yes (n = 36)	11 (31%)	25 (69%)

Abbreviation: OGD, oesophagogastroduodenoscopy.